echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > The company is awarded exclusive rights to two cell immunotherapy Chinese mainland, Hong Kong and Macau.

    The company is awarded exclusive rights to two cell immunotherapy Chinese mainland, Hong Kong and Macau.

    • Last Update: 2020-07-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On July 15th JW Therapeutics and Acepodia, an American biotech company focused on the development of cancer immunotherapy, jointly announced an exclusive priority licensing cooperation agreement, which gave the company's two cell immunotherapy candidates ACE1702 and ACE1655 exclusive and commercialized in Chinese mainland, Hong Kong and Macau, the two products in the research will be developed for the treatment of solid tumors and blood system malignanciesUnder the cooperation agreement, Acepodia will receive a contract authorization, a phased payment, and a sales entitlement, the exact amount of which is not disclosedAcepodia is an American biotech company, according to a press release, the company's allogeneic cell therapy platform is based on its proprietary "off-the-shelf" natural killer cell (oNK), which has strong anti-tumor activityAcepodia's proprietary ACC ™ (Antibody Cell Complex) technology adheres antibodies to proteins on the cell membranes of self-developed oNK cells with therapeutic potential to enhance the lethality of tumor cellsAce1702 is a cell therapy targeting HER2 that targets herNK cells connected to HER2 antibodies, which is currently in clinical trials, according to Acepodia's official websitein both in vivo and in vitro studies, ACE1702 showed enhanced tumor cell activityalso maintained good safety in GLP toxicology researchopen information channels and did not provide details of another drug in the study, ACE1655"We are pleased to partner with Acepodia to advance clinical advances™ in NK cell therapy and ultimately bring these innovative cell therapies to patients," said James Li, CEO of Acepodia, incofAcepodia(Acepodia has used a wide range of methods to provide more potential clinical treatment options for the treatment of solid tumors and hematologic malignancies, and to expand the production of targeted cell therapies as needed as appropriateDrSonny Hsiao, CEO of" Acepodia, said that this collaboration, which brings together the research capabilities and innovative cell therapy technologies of the Expo, and the cancer immunology research and development capabilities of the drug, will help both sides develop oNK cell therapy in the field of cancer, and we look forward to working with the drug-based Juno to maximize the therapeutic potential of allogeneic and off-the-shelf Founded in 2016, , the drug, is an innovative biopharmaceutical company focused on the development, transformation and application of cell immunotherapy and is in the clinical phase 's leading product for CD19's CAR-T treatment product Serkilunsai injection (tentative), in China's listing application has been june 30 this year by the State Drug Administration of China (NMPA) acceptance so far, the company has completed a total of more than $200 million in financing, including Round A and B References: s1 JW therapeutics to receive exclusives todevelop and commercialize ACE1702 and ACE1655 Retrieved July 14, 2020, from the official website of the company from the drug Mingjuno submitted its first new drug listing application, targeting CD19's CAR-T therapeutic products RetrievedJul 01, 2020, from
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.